Details

Autor(en) / Beteiligte

• Cao, Wenwen
• Zhu, Yu
• Wu, Fapu
• Tian, Yang
• Chen, Zhaoming
• Xu, Weijia
• Liu, Senyao
• Liu, Tingting
• Xiong, Hu

Titel

Three Birds with One Stone: Acceptor Engineering of Hemicyanine Dye with NIR‐II Emission for Synergistic Photodynamic and Photothermal Anticancer Therapy

Ist Teil von

• Small (Weinheim an der Bergstrasse, Germany), 2022-12, Vol.18 (49), p.e2204851-n/a

Ort / Verlag

Germany: Wiley Subscription Services, Inc

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• It is challenging to develop a near‐infrared (NIR) small molecular photosensitizer for synergistic phototherapy in deep tissues. Herein, first, a heavy‐atom‐free NIR hemicyanine photosensitizer (BHcy) for 808 nm light‐mediated synergistic photodynamic therapy/photothermal therapy (PDT/PTT) anticancer therapy by leveraging the acceptor engineering strategy is reported. This strategy endows BHcy with a more planar and larger π‐conjugated structure, resulting in long NIR absorption/emission at 770/915–1200 nm as well as enhanced singlet oxygen (1O2) generation ability and photothermal effect, which is ascribed to the reduced energy levels of excited singlet/triplet states and the promoted intersystem crossing process. Notably, BHcy‐based nanoparticles (BHcy‐NPs) exhibit efficient 1O2 yield (12.9%) and high photothermal conversion efficiency (55.1%). More importantly, BHcy‐NPs are able to significantly kill cancer cells by destroying main organelles and inhibit tumor growth in vivo after a single irradiation. Overall, this study provides a strategy to design new heavy‐atom‐free PDT/PTT agents for potential clinical applications. By virtue of the acceptor engineering strategy, a heavy‐atom‐free hemicyanine photosensitizer BHcy with a more planar and larger π‐conjugated structure is developed. It displays efficient singlet oxygen (1O2) production and a high PCE of 55.1%. More importantly, BHcy‐based nanoparticles are successfully applied in NIR‐II guided photodynamic therapy and photothermal therapy synergistic anticancer therapy under 808 nm laser irradiation.